Cover Image

PAPERBACK
$43.50



View/Hide Left Panel

total disease burden value, 59, 60

vaccine preventable illness, 182–183

EPI, see World Health Organization’s Expanded Program on Immunization

Epidemic meningococcal meningitis, 256–259

Epidemics, widespread, 114–115, 118

Equity considerations, 106–111

Equivalent, annualized, 34

Eradication, disease, 115

Escherichia coli, enterotoxigenic, see Enterotoxigenic Escherichia coli

Estimates

reasons for, 30

sources of, 27

Expanded Program on Immunization, see World Health Organization’s Expanded Program on Immunization

Expenditures

annual, 94

discount rate and, 137

hypothetical, 38

F

Fertility control, 107

Formalin-inactivated cell culture vaccine, 233

Formalin-inactivated mouse brainvaccine, 233

G

Global health benefit, potential, 39, 121

Glomerulonephritis, acute post-streptococcal (AGN), 338

Gonorrhea, 56

Government-industry relations, 422

Group A streptococcus (GrAS), see Streptococcus A

H

Haemophilus influenzae type b

annual number of vaccinees and delay in benefits, 87

as candidate, 5

disease burden, 149–158, 188–191

disease description, 186–187

disease distribution, 188–190

health benefits and expenditures associated with, 124

host immune response, 187–188

pathogen description, 187

prediction tables, 64–65, 68–69

probable vaccine target population, 190–192

prospects for immunizing against, 186–194

prospects for vaccine development, 192–194

relationships between expenditures and health benefits, 128–129

suitability for vaccine control, 192

times associated with, 91

total disease burden value, 59, 60

vaccine preventable illness, 190, 192

HAV, see Hepatitis A virus

HBM (health belief model), 78

HBV, see Hepatitis B virus

Health belief model (HBM), 78

Health benefit

associated with candidate vaccines, 82–105

calculating potential, 82–84

comparing, 104

determination of, 6–9

expected, 76

possible, 95, 100–104

potential, see Potential health benefits

steady-state yield of, 90

times for occurrence of vaccine-associated, 86

Health benefit rankings, 13

Health-related investments, priority setting for, 19–29

Heart disease, rheumatic (RHD), 339, 343–345

Hepatitis A virus (HAV)

annual number of vaccinees and delay in benefits, 87

as candidate, 5

disease burden, 198–203

disease burden estimates, 7, 8, 47

disease description, 197–198

disease distribution, 198–202

health benefits and expenditures associated with, 124

host immune response, 198

pathogen description, 198

prediction tables, 64–65, 68–69

probable vaccine target population, 202, 204

prospects for immunizing against, 197–206

prospects for vaccine development, 205–206

relationships between expenditures and health benefits, 128–129

suitability for vaccine control, 204–205

times associated with, 91

total disease burden value, 52–53, 59, 60

vaccine preventable illness, 204

Hepatitis B, acute, 210–211, 212

Hepatitis B virus (HBV)

annual number of vaccinees and delay in benefits, 87

as candidate, 5

disease burden, 210–216

disease description, 208–209

disease distribution, 210–213

health benefits and expenditures associated with, 124

host immune response, 209

pathogen description, 209

prediction tables, 64–65, 68–69

probable vaccine target population, 213, 217

prospects for immunizing against, 208–219

prospects for vaccine development, 217–219

relationships between expenditures and health benefits, 128–129

suitability for vaccine control, 217

times associated with, 91

total disease burden value, 59, 60

vaccine preventable illness, 217

Hepatocellular carcinoma, primary (PHC), 211, 213, 214

Hospitalization, days of, 108

Host immune response

dengue virus, 171

enterotoxigenic Escherichia coli, 179

Haemophilus influenzae type b, 187–188

hepatitis A virus, 198

hepatitis B virus, 209

Japanese encephalitis virus, 225

Mycobacterium leprae, 242

Neisseria meningitidis, 254–255

parainfluenza viruses, 268

Plasmodium spp., 276–277

rabies virus, 290

respiratory syncytial virus, 300

rotavirus, 310



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement